Valuation: Abivax

Market Cap 7.05B 7.91B 6.57B 5.98B 11.28B 762B 11.35B 79.42B 30.87B 389B 29.71B 29.06B 1,249B P/E 2026 *
-20.2x
P/E 2027 * -20.2x
Enterprise Value 6.03B 6.77B 5.62B 5.12B 9.65B 652B 9.71B 67.91B 26.4B 332B 25.4B 24.85B 1,068B EV / Sales 2026 *
1,513x
EV / Sales 2027 * 83.9x
Free-Float
92.2%
Yield 2026 *
-
Yield 2027 * -
1 day-3.11%
1 week-1.22%
Current month-7.86%
1 month-17.11%
3 months-40.07%
6 months-20.22%
Current year-32.81%
1 week 79.85
Extreme 79.85
88.1
1 month 79.65
Extreme 79.65
105.1
Current year 60.45
Extreme 60.45
139
1 year 60.45
Extreme 60.45
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 4.51
Extreme 4.51
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Exercice

Chief Executive Officer

35,456 0.0406%
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Exercice

Chief Executive Officer

17,728 0.0222%
Change 5-day change 1-year change 3-year change Capi.($)
-3.11%-1.22%+12.05%+506.45% 8.19B
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.88%+19.75%+78.35% 57.39B
+1.63%+0.98%+3.83%+38.21% 47.64B
+0.50%+1.32%+344.62%+753.25% 44.29B
+3.05%-1.58%+28.78%+35.46% 42.5B
+1.00%+0.22%+5.17%+113.80% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.76%-0.89%-7.44%-11.43% 24.34B
Average +0.78%-0.33%+49.68%+168.92% 39.87B
Weighted average by Cap. +1.40%-0.78%+57.12%+148.26%

Financials

2026 *2027 *
Net sales 3.99M 4.47M 3.72M 3.38M 6.38M 431M 6.42M 44.9M 17.45M 220M 16.79M 16.43M 706M 71.87M 80.64M 67M 60.99M 115M 7.77B 116M 809M 315M 3.96B 303M 296M 12.73B
Net income -317M -356M -296M -269M -508M -34.31B -511M -3.58B -1.39B -17.5B -1.34B -1.31B -56.24B -291M -327M -272M -247M -466M -31.49B -469M -3.28B -1.28B -16.06B -1.23B -1.2B -51.61B
Net Debt -1.02B -1.15B -953M -868M -1.64B -111B -1.65B -11.52B -4.48B -56.36B -4.31B -4.21B -181B -1.02B -1.15B -952M -866M -1.63B -110B -1.64B -11.5B -4.47B -56.27B -4.3B -4.21B -181B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
98
Date Price Change Volume
26-10-05 €80.90 -3.11% 99,146
26-10-02 €83.50 -0.77% 120,390
26-10-01 €84.15 -4.16% 138,063
26-09-30 €87.80 +4.71% 143,286
26-09-29 €83.85 0.00% 133,837
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
80.90EUR
Average target price
135.01EUR
Spread / Average Target
+66.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock